PFE's oncology portfolio, boosted by Seagen and late-stage pipeline assets, may fuel growth amid lackluster stock performance ...

The debate between CAR T-cell therapy and bispecific antibodies is not a rivalry but a question of sequencing, ...

Sales of the vaccine have been declining due to weak demand trends in China amid an economic slowdown. Gardasil sales ...

Surovatamig shows promise, but needs to outperform established therapies such as Blincyto and Aucatzyl.

AstraZeneca, Pfizer and more are leveraging the computational power of AI to better design trials, predict the potential ...

The initial report of monotherapy with the BCL-2 inhibitor venetoclax showed it had durable clinical activity and favorable ...

Recent collaborations highlight a growing interest in building a multiomics-based understanding of health and disease.

The green light in the US is the first worldwide for Enflonsia ( clesrovimab) and makes the long-acting antibody the first ...

Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly ...

Merck’s shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

The global respiratory syncytial virus respiratory syncytial virus treatment market is undergoing rapid growth, driven by rising vaccine uptake, impr ...